Literature DB >> 26818616

The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review.

Ami D Sperber1, Dan Dumitrascu2, Shin Fukudo3, Charles Gerson4, Uday C Ghoshal5, Kok Ann Gwee6, A Pali S Hungin7, Jin-Yong Kang8, Chen Minhu9, Max Schmulson10, Arkady Bolotin1, Michael Friger1, Tamar Freud1, William Whitehead11.   

Abstract

OBJECTIVES: The global prevalence of IBS is difficult to ascertain, particularly in light of the heterogeneity of published epidemiological studies. The aim was to conduct a literature review, by experts from around the world, of community-based studies on IBS prevalence.
DESIGN: Searches were conducted using predetermined search terms and eligibility criteria, including papers in all languages. Pooled prevalence rates were calculated by combining separate population survey prevalence estimates to generate an overall combined meta-prevalence estimate. The heterogeneity of studies was assessed.
RESULTS: 1451 papers were returned and 83, including 288 103 participants in 41 countries, met inclusion criteria. The mean prevalence among individual countries ranged from 1.1% in France and Iran to 35.5% in Mexico. There was significant variance in pooled regional prevalence rates ranging from 17.5% (95% CI 16.9% to 18.2%) in Latin America, 9.6% (9.5% to 9.8%) in Asia, 7.1% (8.0% to 8.3%) in North America/Europe/Australia/New Zealand, to 5.8% (5.6% to 6.0%) in the Middle East and Africa. There was a significant degree of heterogeneity with the percentage of residual variation due to heterogeneity at 99.9%.
CONCLUSIONS: The main finding is the extent of methodological variance in the studies reviewed and the degree of heterogeneity among them. Based on this, we concluded that publication of a single pooled global prevalence rate, which is easily calculated, would not be appropriate or contributory. Furthermore, we believe that future studies should focus on regional and cross-cultural differences that are more likely to shed light on pathophysiology. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  EPIDEMIOLOGY; FUNCTIONAL BOWEL DISORDER; IRRITABLE BOWEL SYNDROME

Mesh:

Year:  2016        PMID: 26818616     DOI: 10.1136/gutjnl-2015-311240

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  134 in total

1.  Chronic Pain Syndromes and Their Laryngeal Manifestations.

Authors:  Krzysztof Piersiala; Lee M Akst; Alexander T Hillel; Simon R Best
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-06-01       Impact factor: 6.223

2.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

3.  Perceived Stress, Its Physiological Correlates, and Quality of Life in Patients With Irritable Bowel Syndrome.

Authors:  Kristen R Weaver; Gail D'Eramo Melkus; Jason Fletcher; Wendy A Henderson
Journal:  Biol Res Nurs       Date:  2018-02-05       Impact factor: 2.522

4.  Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome.

Authors:  Jørgen Valeur; Milada Cvancarova Småstuen; Torunn Knudsen; Gülen Arslan Lied; Arne Gustav Røseth
Journal:  Dig Dis Sci       Date:  2018-01-04       Impact factor: 3.199

5.  Does irritable bowel syndrome increase the risk of interstitial cystitis/bladder pain syndrome? A cohort study of long term follow-up.

Authors:  Kun-Min Chang; Ming-Huei Lee; Hsuan-Hung Lin; Shang-Liang Wu; Huei-Ching Wu
Journal:  Int Urogynecol J       Date:  2021-02-23       Impact factor: 2.894

6.  Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome.

Authors:  M Connell; A Shin; T James-Stevenson; H Xu; T F Imperiale; J Herron
Journal:  Neurogastroenterol Motil       Date:  2018-08-01       Impact factor: 3.598

7.  A prospective study on incidence, risk factors, and validation of a risk score for post-infection irritable bowel syndrome in coastal eastern India.

Authors:  Prasanta Kumar Parida; Debakanta Mishra; Girish Kumar Pati; Preetam Nath; Kaibalya Ranjan Dash; Sambit Kumar Behera; Suryakanta Parida; Chitta Ranjan Khatua; Subhendu Panigrahi; Amarendra Mahapatra; Hemant Kumar Khuntia; Shivaram Prasad Singh
Journal:  Indian J Gastroenterol       Date:  2019-04-04

8.  Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.

Authors:  M Simrén; O S Palsson; S Heymen; A Bajor; H Törnblom; W E Whitehead
Journal:  Neurogastroenterol Motil       Date:  2016-08-31       Impact factor: 3.598

Review 9.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 10.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.